Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens

Inclusion Criteria:

- Type 2 diabetes (diagnosed clinically) for 24 weeks or longer prior to randomisation
(visit 2)

- Insulin naïve subjects (Allowed are: Previous short term insulin treatment no longer
than or equal to 14 days in total; Treatment during hospitalisation or during
gestational diabetes is allowed for periods longer than 14 days in total)

- Current treatment: Metformin alone or metformin in any combination of 1 or 2
additional OADs (oral anti-diabetic drug) including an insulin secretagogue
(sulfonylurea or glinide), dipeptidyl peptidase IV (DPP-IV) inhibitors,
alpha-glucosidase inhibitors or thiazolidinediones (TZDs) - all with unchanged dosing
for at least 12 weeks prior to randomisation (visit 2). Metformin dose, alone or in
combination (including fixed combination), must be at least 1000 mg daily

- HbA1c (glycosylated haemoglobin) 7.0-10.0% (both inclusive)

- BMI (Body Mass Index) below or equal to 45 kg/m^2

- Ability and willingness to adhere to the protocol including self measurement of
plasma glucose

Exclusion Criteria:

- Treatment with GLP-1 (glucagon like peptide) receptor agonists within the last 12
weeks prior to randomisation (visit 2)

- Recurrent severe hypoglycaemia (more than one severe hypoglycaemic event during the
last 12 months) or hypoglycaemic unawareness as judged by the Investigator (trial
physician)

- Previous participation in this trial. Participation is defined as randomised.
Re-screening is allowed once during the recruitment period

- Known or suspected hypersensitivity to trial products or related products

- The receipt of any investigational drug within 4 weeks prior to randomisation (visit
2)

- Anticipated significant lifestyle changes during the study, e.g. shift work
(including permanent night/evening shift workers) as well as highly variable eating
habits